论文部分内容阅读
目的 :探讨超分割放射治疗非小细胞肺癌治疗效果及毒副作用。方法 :对 1995年 6月 - 1998年 8月将 92例 NSCL C随机分成超分割放疗 (HF)组和常规分割放疗 (CF)组。结果 :HF组完全缓解率 (CR)和总有效率 (CR+PR)分别为 2 3.9%和 89.1% ,显著高于 CF组的 15 .2 %和 6 0 .9%(P<0 .0 5 )。两组 1年生存率和局部控制率无显著性差异 (P>0 .0 5 )。 HF组 2、3年生存率和局部控制率分别为 5 2 .2 %、2 8.3%和 4 7.8%、 37.0 % ,也显著高于 CF组的 2 3.9%、 13.0 %和 2 6 .1%、8.7%(P<0 .0 5 )。 HF组急性放射性食管炎发生率较 CF组为高 (P<0 .0 5 ) ,放射性气管炎、放射性肺炎和骨髓抑制均无显著性差异 (P>0 .0 5 ) ,全组患者均能耐受治疗 ,无需特殊处理。结论 :超分割放射治疗方案治疗NCSL C明显优于 CF方案 ,毒副作用较轻 ,患者均可耐受 ,可提高局部控制率和降低复发率 ,进一步提高生存率
Objective: To investigate the therapeutic effect and side effects of hyperfraction radiotherapy in non-small cell lung cancer. Methods: From June 1995 to August 1998, 92 patients with NSCL C were randomly divided into hyperfractionated radiotherapy (HF) group and conventional radiofrequency (CF) group. Results: The complete remission rate (CR) and total effective rate (CR + PR) in HF group were 23.9% and 89.1%, respectively, which were significantly higher than those in CF group (15.2% vs 60.9%, P < 5). There was no significant difference in one-year survival rate and local control rate between the two groups (P> 0.05). The 2-year and 3-year survival rates and local control rates of HF group were 52.2%, 28.3% and 41.8%, 37.0%, respectively, which were also significantly higher than those of 2 3.9%, 13.0% and 26.1% , 8.7% (P <0.05). The incidence of acute radiation esophagitis in HF group was higher than that in CF group (P <0.05), but there was no significant difference between radiation bronchitis, radiation pneumonitis and myelosuppression (P> 0.05) Tolerance to treatment, without special treatment. Conclusion: Hyperfraction radiotherapy is superior to CF in the treatment of NCSL C, with less toxic and side effects, which can be tolerated in both patients and controls. It can improve the local control rate and reduce the recurrence rate and further improve the survival rate